Action FDA approved Qalsody (tofersen) to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS). Qalsody is an antisense oligonucleotide that targets SOD1 mRNA to reduce the synthesis of SOD1 protein. The approval was based on a reduction in plasma neurofilament light (NfL), a blood-based
Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older
COVID-19 vaccination directly saved at least 1,004,927 lives across Europe between December 2020 and March 2023, according to new research being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark (15-18 April). The new estimates by WHO/Europe and presented at the conference by Dr Margaux Meslé, Epidemiologist at
A nonstatin therapy approved almost 3 years ago to treat low-density lipoprotein (LDL) cholesterol also cuts the risk of major cardiovascular events, especially heart attacks, according to data presented. Bempedoic acid, approved in February 2020 as Nexletol (Esperion), reduced by 13% the risk of a 4-part composite end point of major adverse cardiovascular events (MACE),
Noninvasive approach is fast, cost-effective and could be used to treat a variety of cancers doptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies
A new antibody drug by pharmaceutical company inflaRx received FDA emergency use authorization to treat critically ill Covid-19 patients. One of the greatest hurdles for monoclonal antibody development during the Covid-19 pandemic is the ongoing mutation of the SARS-CoV-2 virus. Most antibodies introduced throughout the pandemic targeted the virus spike protein, which mutates significantly with every emerging
A study published in the New England Journal of Medicine has shown that there may finally be an alternative to amputation for patients suffering from chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. This study, co-led by University Hospitals (UH) Harrington Heart & Vascular Institute, could lead to the first FDA approval of
COVID is not yet under control. Despite a bevy of vaccines, monoclonal antibodies, and antivirals, the virus continues to mutate and elude us. One solution that scientists have been exploring since the early days of the pandemic may come in the form of tiny antibodies derived from llamas, which target various parts of the SARS-CoV-2 spike protein.
A joint research team of POSTECH, Kyungpook National University, and Korea University Anam Hospital developed an osteogenic barrier coating material that maximizes the effect of guided bone regeneration (GBR) for implant placements. One of the key factors of success in a dental implant is the condition of the periodontium around the implant. A higher long-term
For most people, getting burrs stuck to your clothes during a hike is nothing more than a nuisance, something to pick off and throw out when you get home. But for scientists at the Center for Engineering MechanoBiology (CEMB), the hooks on these little hitchhikers are inspiring new suturing schemes for surgical reattachment of tendon to
